Dapagliflozin - Pharmacy Freak

Mechanism of Action of Dapagliflozin

April 10, 2026July 6, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Dapagliflozin is an oral sodium–glucose co-transporter 2 (SGLT2) inhibitor, used to treat type 2 diabetes mellitus (T2DM). Additionally, it offers benefits in heart failure and chronic kidney disease, independent of its glucose-lowering effects. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral, once daily Bioavailability ~78% Protein Binding ~91% Metabolism Glucuronidation (UGT1A9) Half-life … Read more

Mechanism of Action of SGLT2Inhibitors

April 10, 2026July 3, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction SGLT2 inhibitors, also known as “gliflozins,” are a class of oral antidiabetic agents primarily used to manage type 2 diabetes mellitus. They also exhibit notable cardiovascular and renal protective effects, making them valuable in treating heart failure and chronic kidney disease, even in non-diabetic patients. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Absorption … Read more

Mechanism of Action of Farxiga (Dapagliflozin)

April 10, 2026July 1, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Dapagliflozin (trade name Farxiga) is a sodium–glucose co‑transporter 2 (SGLT2) inhibitor used in type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF). It lowers blood glucose by promoting renal excretion of glucose and also provides cardiovascular and renal benefits beyond glycemic control. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral … Read more